• Lauren Harms, Gloria G Parras, Patricia T Michie, and Manuel S Malmierca.
• School of Biomedical Sciences and Pharmacy, University of Newcastle, Australia; Hunter Medical Research Institute, University of Newcastle, Australia; Centre for Brain and Mental Health Research, University of Newcastle, Australia. Electronic address: lauren.harms@newcastle.edu.au.
• Neuroscience. 2021 Feb 21; 456: 106-113.

AbstractMismatch negativity (MMN) is an electrophysiological signature that occurs in response to unexpected stimuli. It is often referred to as a measure of memory-based change detection, because the elicitation of a prediction error response relies on the formation of a prediction, which in turn, is dependent upon intact memory of previous auditory stimulation. As such, the MMN is altered in conditions in which memory is affected, such as Alzheimer's disease, schizophrenia and healthy aging. The most prominent pharmacological finding for MMN strengthens the link between MMN and synaptic plasticity, as glutamate N-methyl-d-aspartate receptor (NMDA-R) antagonists reduce the MMN response. However, recent data has begun to demonstrate that the link between NMDA-R function and MMN is not as clear as once thought, with low dose and low affinity NMDA-R antagonists observed to facilitate MMN.Copyright © 2020 IBRO. Published by Elsevier Ltd. All rights reserved.

13 keywords...

hide…